The results of the OlympiA clinical trial show that olaparib reduces breast cancer recurrence in patients with early-stage breast cancer with BRCA1 or BRCA2 mutations by 42%.
The results of this international study conducted in Australia by the Breast Cancer Test are: New England Journal of Medicine It will be presented at the 2021 Annual Meeting of the American Society of Clinical Oncology on 6/6/21.
The OlympiA clinical trial was coordinated internationally by the Breast International Group and recruited 1,836 patients worldwide, including 60 women from Australia.
OlympiA found that olaparib tablets given twice daily to patients with BRCA1 and BRCA2 mutations after completing chemotherapy are more likely to remain free of invasive or metastatic cancer. did. This is a phase III clinical trial that tested the efficacy and safety of olaparib tablets and placebo as adjuvant therapies.
Professor Kelly-Anne Phillips, chair of the Olympi A Clinical Trials and Medical Oncologist Breast Cancer Studies Research Committee at the Peter MacCallum Cancer Center, states that the results offer new treatment options for patients with early-stage breast cancer.
“One of the biggest concerns patients have is the recurrence of breast cancer. OlympiA clinical trials have identified new treatments for patients with early-stage breast cancer who have a genetic mutation in the BRCA1 or BRCA2 gene. After the initial treatment is complete, it can help prevent the recurrence of breast cancer and the spread of the cancer, “said Professor Phillips.
“Approximately 5% of all breast cancer patients have a BRCA1 or BRCA2 gene mutation, which represents approximately 1,000 women diagnosed with breast cancer each year in Australia. These women are usually at a young age. Breast cancer is often diagnosed and often suffers from a particularly aggressive form of breast cancer.
“Olaparib ensures that cancer cells are more likely to die by taking advantage of the inherent defects in DNA repair that are present in cancer in people with BRCA1 or BRCA2 mutations.”
“Our findings are an important step forward in precision treatment of breast cancer and offer new treatment options.”
“The findings also mean that genetic testing for BRCA1 and BRCA2 is more likely to be more routine for all women newly diagnosed with breast cancer. It also has genetic abnormalities. Therefore, it has the downstream effect of helping to identify relatives who can be treated on the basis of evidence that can prevent cancer. Therefore, this is not only a step in breast cancer treatment, but It also helps prevent breast cancer. “
“We would like to express our sincere gratitude to all the women who participated in this trial for enabling advances in this treatment and to clinicians and research staff throughout Australia for their contributions to these breakthrough results. Thank you too. “
OlympiA clinical trial results New England Journal of Medicine Available here: https: //www.nejm.org/doi/full/10.1056/NEJMoa2105215
For more information on breast cancer trials, please visit www.breastcancertrials.org.au.
New treatments reduce BRCA breast cancer recurrence by 42%
Source link New treatments reduce BRCA breast cancer recurrence by 42%